Top

Journal of Neurology

Published in:

01-12-2018 | Original Communication

Short-term and long-term effects of immunoadsorption in refractory chronic inflammatory demyelinating polyneuropathy: a prospective study in 17 patients

Authors: Johannes Dorst, Albert C. Ludolph, Makbule Senel, Hayrettin Tumani

Published in: Journal of Neurology | Issue 12/2018

Abstract

Objective

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, autoimmune-inflammatory disease of the peripheral nervous system. Recently, various immunoglobulin G4 (IgG4) type auto-antibodies have been described in patients with CIDP which can effectively be removed by immunoadsorption (IA). Therefore, we prospectively evaluated the therapeutic effect of IA in 17 patients with progressive CIDP not responding to other treatment.

Methods

We prospectively evaluated the course of disease of 17 patients with CIDP who had insufficiently responded to steroids and/or IVIg previously and who received at least one cycle of IA. As clinical outcome parameter, we used a combined CIDP score of three validated scales comprising disability, motor score, and sensitivity. Seven patients received repeated treatments in regular intervals over a prolonged period up to 46 months.

Results

We observed a small, but significant improvement of the overall score after 2 weeks that mainly reflected an improvement of muscle strength. The median value of the combined CIDP score was 308.0 (266.0–374.5) points before IA and 330.0 (290.0–393.5) points 2 weeks after IA (p = 0.019). More importantly, all but one of seven progressive patients who received long-term immunoadsorption in regular intervals stabilized almost completely. Before IA, these patients lost 6.7 (3.0–13.1) points of combined CIDP score per month. During IA, they lost − 0.1 (0.0–0.8) points per month (p < 0.0001).

Interpretation

Our results suggest that IA might constitute a promising and well-tolerated therapeutic alternative in CIDP for short-term and long-term treatment. We showed that long-term treatment with IA in regular intervals can stabilize the course of disease at least in a subgroup of patients.

Van den Bergh PY, Hadden RD, Bouche P, Cornblath DR, Hahn A, Illa I, Koski CL, Leger JM, Nobile-Orazio E, Pollard J, Sommer C, van Doorn PA, van Schaik IN (2010) European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision. Eur J Neurol 17(3):356–363CrossRef

Querol L, Devaux J, Rojas-Garcia R, Illa I (2017) Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications. Nat Rev Neurol 13(9):533–547CrossRef

Illa I (2017) ARTHUR ASBURY LECTURE: Chronic inflammatory demyelinating polyradiculoneuropathy: clinical aspects and new animal models of auto-immunity to nodal components. J Peripher Nerv Syst 22(4):418–424CrossRef

Jacob S, Rajabally YA (2009) Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol 7(4):337–342CrossRef

Zollner S, Pablik E, Druml W, Derfler K, Rees A, Biesenbach P (2014) Fibrinogen reduction and bleeding complications in plasma exchange, immunoadsorption and a combination of the two. Blood Purif 38(2):160–166. https://doi.org/10.1159/000367682 CrossRefPubMed

Kohler W, Bucka C, Klingel R (2011) A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis. J Clin Apher 26(6):347–355. https://doi.org/10.1002/jca.20317 CrossRefPubMed

Lieker I, Slowinski T, Harms L, Hahn K, Klehmet J (2017) A prospective study comparing tryptophan immunoadsorption with therapeutic plasma exchange for the treatment of chronic inflammatory demyelinating polyneuropathy. J Clin Apher 32(6):486–493CrossRef

Klingel R, Heibges A, Fassbender C (2009) Plasma exchange and immunoadsorption for autoimmune neurologic diseases—current guidelines and future perspectives. Atheroscler Suppl 10(5):129–132. https://doi.org/10.1016/s1567-5688(09)71827-6 CrossRefPubMed

Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA (2002) Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 72(5):596–601CrossRef

10.

Breiner A, Barnett C, Bril V (2014) INCAT disability score: a critical analysis of its measurement properties. Muscle Nerve 50(2):164–169CrossRef

11.

Merkies IS, Hughes RA, Donofrio P, Bril V, Dalakas MC, Hanna K, Hartung HP, Latov N, van Doorn PA, Deng C (2010) Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study. J Peripher Nerv Syst 15(3):208–215CrossRef

12.

Galldiks N, Burghaus L, Dohmen C, Teschner S, Pollok M, Leebmann J, Frischmuth N, Hollinger P, Nazli N, Fassbender C, Klingel R, Benzing T, Fink GR, Haupt WF (2011) Immunoadsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to first-line treatment. Eur Neurol 66(4):183–189. https://doi.org/10.1159/000331011 CrossRefPubMed

13.

Zinman LH, Sutton D, Ng E, Nwe P, Ngo M, Bril V (2005) A pilot study to compare the use of the Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy. Transfus Apher Sci 33(3):317–324. https://doi.org/10.1016/j.transci.2005.07.010 CrossRefPubMed

Title: Short-term and long-term effects of immunoadsorption in refractory chronic inflammatory demyelinating polyneuropathy: a prospective study in 17 patients
Authors: Johannes Dorst
Albert C. Ludolph
Makbule Senel
Hayrettin Tumani
Publication date: 01-12-2018
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 12/2018
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-018-9082-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Short-term and long-term effects of immunoadsorption in refractory chronic inflammatory demyelinating polyneuropathy: a prospective study in 17 patients

Abstract

Objective

Methods

Results

Interpretation

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Interpretation

Please log in to get access to this content

Other articles of this Issue 12/2018

Identifying barriers to help-seeking for sexual dysfunction in multiple sclerosis

Perfusion-CT imaging in epileptic seizures

Acute antiepileptic drug use in intensive care units

Link between overweight/obese in children and youngsters and occurrence of multiple sclerosis

Dilemma of multiple system atrophy and spinocerebellar ataxias

Cerebral small vessel disease burden and functional and radiographic outcomes in intracerebral hemorrhage